Answers by TheMediTary.Com - Last updated: 13-Jul-2023
Ninlaro (ixazomib) does not cause shingles, but while having Ninlaro treatment there is an increased risk of shingles in patients who have previously had chickenpox (varicella-zoster virus), as the virus that is dormant can be reactivated when the immune system is suppressed.
In the clinical trial the overall shingles rate in the Ninlaro group was 4% and the placebo group was 2%, meaning the Ninlaro rate of shingles was 2% higher than the placebo group.
By taking antiviral medication, the shingles rate in the Ninlaro group decreased to below 1%.
| Shingles rate | Ninlaro treatment group | Placebo treatment group |
|---|---|---|
| Overall rate | 4% | 2% |
| With antiviral prophylaxis | ＜1% | information not available |
| Without antiviral prophylaxis | 6% | information not available |